Q2 2025 Knight Therapeutics Inc Earnings Call Transcript
Key Points
- Knight Therapeutics Inc (KHTRF) achieved a record high adjusted revenues of $197 million for the first half of 2025, driven by a 15% organic growth on a constant currency basis.
- The company added over 50 products to its portfolio through the Paladin and Sumitomo transactions, including five pipeline and early launch assets.
- Knight Therapeutics Inc (KHTRF) expanded its agreement with Helsin and re-launched Onicit in Brazil and Mexico, enhancing its market presence.
- The company secured a $50 million US dollar revolving credit facility with National Bank, with plans to increase it to $100 million US dollars, ensuring financial flexibility.
- Knight Therapeutics Inc (KHTRF) reported a 15% increase in revenues for Q2 2025 compared to the same quarter last year, driven by the growth of key promoted products and transactions.
- The gross margin decreased to 46% in Q2 2025 from 48% in the same period last year, mainly due to product mix and severance costs related to facility closures.
- Operating expenses increased by 27% compared to the same period last year, driven by acquisition costs and pre-launch investments.
- Knight Therapeutics Inc (KHTRF) reported a net loss of $5.7 million in Q2 2025, primarily due to market-to-market revaluations of strategic fund investments.
- The company experienced a decrease in the gross margin percentage due to product mix and severance costs related to facility closures.
- Knight Therapeutics Inc (KHTRF) has not yet secured additional orders from the Brazilian Ministry of Health for the rest of the year, creating uncertainty in future revenue from this source.
Good morning ladies and gentlemen and I will be your operator. Welcome to Knight Therapeutics. Second quarter 2025 results conference call. Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature necessarily involve risk and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.
The company considers the assumptions on which these forward-looking statements are based to be reasonable. They were prepared, but cautious that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether there are results of information, future events, except as required by law.
We would also like to remind you questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
